Study for Adults with Newly Diagnosed Glioblastoma or Gliosarcoma

IRB/UVA Tracking #
Principal Investigator
David Schiff
Jennifer De Jong
Contact Phone
Official Trial Title
INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)
Study Description

The Department of Neurology is conducting a study to determine whether experimental chemotherapy improves overall survival compared to standard chemotherapy in patients with newly diagnosed glioblastoma or gliosarcoma.
Adults who have recently been diagnosed with glioblastoma or gliosarcoma may be eligible for this trial.
Participants may be randomized to the standard of care control arm, or one of several experimental treatment arms. Standard of care includes radiation and temozolomide. The investigational treatments may include standard of care with adjuvant treatments such as abemaciclib or neratinib. Some arms may include treatments in place of temozolomide.
Participants will have routine neurological and physical exams, blood sampling for safety, and tumor evaluations done by MRI. Participants will receive the investigational drug as long as the tumor doesn’t grow significantly and they do not experience unacceptable drug effects. Routine care expenses will be billed to the insurance provider and then to the patient if not covered. The investigational drug will be provided free of charge.
Ages: Adults (age 18+)


No Compensation